Novartis will receive an exclusive option to negotiate commercialization deal.
Novartis Vaccines and Diagnostics will provide Dynavax Technologies a supply of trivalent influenza vaccine, an essential component of Dynavax’ universal influenza vaccine. It will be used in clinical trials and for commercial purposes.
As a result, Dynavax will conduct early-stage development through a defined proof-of-concept. Novartis will receive an exclusive option to negotiate a joint development and commercialization agreement with Dynavax. If the firm exercises this right, Dynavax would retain co-commercialization rights in the U.S. and receive product royalties outside of the U.S.
Should the option not be exercised, Novartis remains committed to providing commercial supply of trivalent influenza vaccine with pre-agreed commercial terms, and Dynavax retains the right to independently continue with late-stage development and commercialization.
The Dynavax universal influenza caccine combines a second-generation TLR9 agonist with two conserved influenza antigens, nucleoprotein and the extracellular domain of matrix protein 2, and a trivalent influenza vaccine. The Dynavax vaccine is designed to be differentiated from other influenza vaccines by providing both an adjuvant effect to enhance the immunogenicity of the seasonal vaccine and cross-strain protection via conserved influenza antigens, according to the company.
